Venous thromboembolism following total knee replacement.

Bryan Y. Choi, Michael H. Huo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Venous thromboembolic disease (VTE) remains the most common and potentially fatal complication following total knee replacement (TKR). Its incidence has been reported in excess of 50% if no prophylaxis is used. Even with current prophylaxis regimens, VTE incidence remains high in the range of 25% to 30%. Three prophylaxis regimens are recommended according to the guidelines put forth by the American College of Chest Physicians: 1) low-molecular-weight heparin, 2) indirect factor Xa inhibitor, and 3) adjusted-dose warfarin. Phase II and III clinical trials are currently underway to evaluate the efficacy and safety of newer antithrombotic agents as prophylaxis against VTE following TKR.

Original languageEnglish (US)
Pages (from-to)31-35
Number of pages5
JournalJournal of surgical orthopaedic advances
Volume16
Issue number1
StatePublished - Mar 2007

Fingerprint

Knee Replacement Arthroplasties
Venous Thromboembolism
Phase III Clinical Trials
Phase II Clinical Trials
Fibrinolytic Agents
Low Molecular Weight Heparin
Incidence
Warfarin
Guidelines
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Venous thromboembolism following total knee replacement. / Choi, Bryan Y.; Huo, Michael H.

In: Journal of surgical orthopaedic advances, Vol. 16, No. 1, 03.2007, p. 31-35.

Research output: Contribution to journalArticle

@article{43371766244f420fbb12c7a42e6d1ca7,
title = "Venous thromboembolism following total knee replacement.",
abstract = "Venous thromboembolic disease (VTE) remains the most common and potentially fatal complication following total knee replacement (TKR). Its incidence has been reported in excess of 50{\%} if no prophylaxis is used. Even with current prophylaxis regimens, VTE incidence remains high in the range of 25{\%} to 30{\%}. Three prophylaxis regimens are recommended according to the guidelines put forth by the American College of Chest Physicians: 1) low-molecular-weight heparin, 2) indirect factor Xa inhibitor, and 3) adjusted-dose warfarin. Phase II and III clinical trials are currently underway to evaluate the efficacy and safety of newer antithrombotic agents as prophylaxis against VTE following TKR.",
author = "Choi, {Bryan Y.} and Huo, {Michael H.}",
year = "2007",
month = "3",
language = "English (US)",
volume = "16",
pages = "31--35",
journal = "Journal of the Southern Orthopaedic Association",
issn = "1548-825X",
publisher = "Data Trace Publishing Co.",
number = "1",

}

TY - JOUR

T1 - Venous thromboembolism following total knee replacement.

AU - Choi, Bryan Y.

AU - Huo, Michael H.

PY - 2007/3

Y1 - 2007/3

N2 - Venous thromboembolic disease (VTE) remains the most common and potentially fatal complication following total knee replacement (TKR). Its incidence has been reported in excess of 50% if no prophylaxis is used. Even with current prophylaxis regimens, VTE incidence remains high in the range of 25% to 30%. Three prophylaxis regimens are recommended according to the guidelines put forth by the American College of Chest Physicians: 1) low-molecular-weight heparin, 2) indirect factor Xa inhibitor, and 3) adjusted-dose warfarin. Phase II and III clinical trials are currently underway to evaluate the efficacy and safety of newer antithrombotic agents as prophylaxis against VTE following TKR.

AB - Venous thromboembolic disease (VTE) remains the most common and potentially fatal complication following total knee replacement (TKR). Its incidence has been reported in excess of 50% if no prophylaxis is used. Even with current prophylaxis regimens, VTE incidence remains high in the range of 25% to 30%. Three prophylaxis regimens are recommended according to the guidelines put forth by the American College of Chest Physicians: 1) low-molecular-weight heparin, 2) indirect factor Xa inhibitor, and 3) adjusted-dose warfarin. Phase II and III clinical trials are currently underway to evaluate the efficacy and safety of newer antithrombotic agents as prophylaxis against VTE following TKR.

UR - http://www.scopus.com/inward/record.url?scp=34047219744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047219744&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 31

EP - 35

JO - Journal of the Southern Orthopaedic Association

JF - Journal of the Southern Orthopaedic Association

SN - 1548-825X

IS - 1

ER -